Bayer Issues Earnings Nov. 25; Update Expected On Strategic Realignment
This article was originally published in The Pink Sheet Daily
Executive Summary
Company’s plans to expand its U.S. oncology business and its recent deal with Schering-Plough for primary care product marketing rights in the U.S. are likely to be a focus of discussion. Bayer’s shareholders approve spin-off of Lanxess chemicals/polymers unit.
You may also be interested in...
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.
"Bayer-ly" An Rx Company? Viadur Is Focus Of New Bayer Oncology Unit
Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough
Top Seven Pink Sheet Infographics Of 2023
A visual perspective on key regulatory topics in 2023, from clinical trial diversity to product approval trends and Medicare drug price negotiation.